Flavia Zacconi
- Position
- Associate Professor
- Academic unit
- Department of Organic Chemistry, Faculty of Chemistry and Pharmacy UC
- Lines of Research
- Medicinal, Medicinal, Biological and Organic Chemistry
- Drug design
- Materials, nanotechnology and structural analysis
- Summary
Professor Zacconi holds a B.Sc. and Ph.D. in Chemistry from the Universidad Nacional del Sur, Argentina, where she worked as a teacher and researcher until 2012. In addition, she developed her postdoctoral research at the University of Santiago de Compostela (2009-2011, Spain) and at the Institute of Organic Synthesis (2011-2012, Spain). In 2012 she was part of the STVP-UC Innovation and Entrepreneurship Program (Stanford University, USA). Additionally, Dr. Zacconi has been a visiting professor at Boston College (2014-2015, Massachusetts, USA), University of Sussex (2019-2021, Sussex, UK) and at the University of Notre Dame (2020, Indiana, USA).
She is currently an Associate Professor in the Department of Organic Chemistry of the Faculty of Chemistry and Pharmacy of the Pontificia Universidad Católica de Chile. Also, since 2020 she is Associate Professor at the Institute of Biological and Medical Engineering UC, she also serves as Associate Member of the Center for Research in Nanotechnology and Advanced Materials (CIEN-UC).
His research focuses on the intersections of organic chemistry, medicinal chemistry, engineering and biological chemistry, developing multi- and interdisciplinary research to understand the complexity in the design of molecules with bioactive potential.
- Chemist, Universidad Nacional del Sur, Argentina, 2000.
- Degree in Chemistry, Universidad Nacional del Sur, Argentina, 2003.
- D. in Chemistry, Universidad Nacional del Sur, Argentina, 2009.
- Diploma in University Teaching UC, Pontificia Universidad Católica de Chile, Chile, 2016.
Current Projects
ANID IDeA R&D Advanced Technologies. "New microalgal source optimized for
production of supplement enriched in omega-3 and antioxidants: validation in animal models
and human studies" (2023-2027). Investigator. Funding amount:
660,000,000 CLP.
III Research Results Accelerator Program-Science 2030-CORFO.
"NuNaOx: New Oxygen Transporting Nanosystems for Biomedical Applications
- Study of Apolar Gases" (2024). Principal Investigator. Amount of financing:
3,000,000 CLP.
Fondecyt Regular (2022-2026). "Improving phenotyping of MAFLD patients using Magnetic
Resonance Spectroscopy and Machine Learning". Investigator. Amount of funding:
219.000.000 CLP.
Fondecyt Regular (2021-2025). "Newly piperazinone derivatives with antithrombotic and
anti-inflammatory properties: environmentally friendly synthesis, characterization, and
biological evaluation". Principal Investigator. Amount of financing: 154,804,000 CLP.
Fondecyt Regular (2020-2024). "Hybrids of Tetrahydroquinolines as Multi-Target drugs:
Design, Synthesis, characterization and biological activity". Investigator. Amount of
funding: 158.800.000 CLP.
Previous Projects
I Research Results Accelerator Program-Science 2030-CORFO.
"NuNaOx: New Oxygen Transporting Nanosystems for Biomedical Applications"
(2022-2023). Principal Investigator. Amount of financing: 8,000,000 CLP.
I Concurso Programa acelerador de resultados de investigación-Ciencia 2030-CORFO.
"Extracto concentrado de microalgas como suplemento alimenticio con propiedades
antioxidantes y neuroprotectoras" (2022-2023). Investigator. Amount of funding:
8.000.000 CLP.
Global Strategic Partnership Seed Funding Scheme UTS-UC. "Targeted delivery of Curcumin
liposomes as a therapeutic intervention in chronic obstructive pulmonary disease" (2023).
Principal Investigator. Amount of funding: 10,000 AUD.
Global Strategic Partnership Seed Funding Scheme UTS-UC. "Targeted delivery of
Zerumbone engineered nanoparticles as a therapeutic intervention in chronic obstructive
pulmonary disease" (2022). Principal Investigator. Amount of financing: 10,000 AUD.